{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:18Z","timestamp":1783318518304,"version":"3.54.6"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the increasing use of immune checkpoint inhibitors (ICI) in clinical practice of lung cancer, more immune-related adverse events (irAEs) are being discovered. However, hematologic irAEs (hem-irAEs) were rarely described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Two patients with non-small cell lung cancer were treated with tislelizumab and chemotherapy as the first-line treatment. Immune-related pancytopenia (grade 4 neutropenia, grade 3\u20134 thrombocytopenia, and grade 3 anemia) occurred after the 3rd (Day 144) and 2nd (Day 32) cycles, respectively. Case 1 had concomitant immune-related hepatitis (grade 3) while Case 2 presented with immune-related mucositis and renal insufficiency (grade 2). Bone marrow examination of Case 1 revealed a hypocellular marrow with increased mature lymphocytes. The patients were given granulocyte-stimulating factor (G-CSF), thrombopoietin, component transfusion (platelet-rich buffy coat and apheresis platelets), and corticosteroids (0.72\u20131.64 mg\/kg\/d). Grade 4 neutropenia persisted, with only mild improvements in platelets and red blood cells. Intermittent fever and pulmonary infection were managed with antibacterial and antifungal therapy. Regrettably, both patients died of multiple organ dysfunction syndrome. Naranjo Scale rated tislelizumab-induced pancytopenia as possible in both cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although hem-irAEs are rare, they should be distinguished from chemotherapy-induced myelosuppression. Clinicians should remain vigilant, monitor blood cell counts regularly, and intervene promptly to prevent severe complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1820443","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:04Z","timestamp":1783316284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Fang","family":"Lu","sequence":"first","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkang","family":"Zong","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Pathology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechuan","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis.","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020.","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol."},{"key":"B11","volume-title":"CSCO Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities 2019.","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors.","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review.","volume":"11","author":"Omar","year":"2020","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors.","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis.","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1415748","DOI":"10.3389\/fonc.2024.1415748","article-title":"Case report: a rare case of anti-PD-1 sintilimab-induced agranulocytosis\/severe neutropenia in non-small cell lung cancer and literature review.","volume":"14","author":"Qin","year":"2024","journal-title":"Front Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"973421","DOI":"10.3389\/fonc.2022.973421","article-title":"Case report: a rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review.","volume":"12","author":"Tan","year":"2022","journal-title":"Front Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy.","volume":"80","author":"Michot","year":"2017","journal-title":"Eur J Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","article-title":"Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.","volume":"28","author":"Turgeman","year":"2017","journal-title":"Anticancer Drugs."},{"key":"B20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","article-title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.","volume":"99","author":"Tabchi","year":"2016","journal-title":"Lung Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2018.02.018","article-title":"Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.","volume":"119","author":"Tokumo","year":"2018","journal-title":"Lung Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","article-title":"A case of severe pembrolizumab-induced neutropenia.","volume":"29","author":"Barbacki","year":"2018","journal-title":"Anticancer Drugs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2021-0131","article-title":"Delayed immune-related neutropenia with hepatitis by pembrolizumab.","volume":"14","author":"Nakako","year":"2022","journal-title":"Immunotherapy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/10781552241228774","article-title":"Pembrolizumab-induced agranulocytosis.","volume":"30","author":"Fern\u00e1ndez Mart\u00ednez","year":"2024","journal-title":"J Oncol Pharm Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40425-019-0648-3","article-title":"Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.","volume":"7","author":"Naqash","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e920809","DOI":"10.12659\/AJCR.920809","article-title":"Febrile neutropenia in a patient with non-small cell lung cancer treated with the immune-checkpoint inhibitor nivolumab.","volume":"21","author":"Hisamatsu","year":"2020","journal-title":"Am J Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101439","DOI":"10.1016\/j.rmcr.2021.101439","article-title":"Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report.","volume":"33","author":"Seguchi","year":"2021","journal-title":"Respir Med Case Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2169\/internalmedicine.0278-22","article-title":"Successful steroid treatment of pembrolizumab-induced agranulocytosis that developed after splenectomy in a patient with non-small-cell lung cancer.","volume":"62","author":"Okuzumi","year":"2023","journal-title":"Intern Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/0115748863297885240604111018","article-title":"Treatment of tislelizumab-induced toxic epidermal necrolysis and agranulocytosis: a case report and literature review.","volume":"20","author":"Zhou","year":"2025","journal-title":"Curr Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e00799","DOI":"10.1002\/rcr2.799","article-title":"No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids.","volume":"9","author":"Kanai","year":"2021","journal-title":"Respirol Case Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2147\/TCRM.S144681","article-title":"A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia.","volume":"13","author":"Liu","year":"2017","journal-title":"Ther Clin Risk Manag."},{"key":"B32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2017.01.016","article-title":"High programmed death 1 expression on T cells in aplastic anemia.","volume":"183","author":"Zhao","year":"2017","journal-title":"Immunol Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CJI.0000000000000293","article-title":"Immune-related neutropenia following treatment with immune checkpoint inhibitors.","volume":"43","author":"Finkel","year":"2020","journal-title":"J Immunother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer.","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10637-018-0561-5","article-title":"Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.","volume":"36","author":"Ogawa","year":"2018","journal-title":"Invest New Drugs."},{"key":"B36","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines.","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann Oncol."},{"key":"B37","first-page":"638","article-title":"Chinese society of clinical oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy-related neutropenia (Version 2021).","volume":"26","year":"2021","journal-title":"Chin Clin Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer."},{"key":"B39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-8588(18)30672-5","article-title":"Hematologic manifestations of bacterial and fungal infections.","volume":"1","author":"Strausbaugh","year":"1987","journal-title":"Hematol Oncol Clin North Am."},{"key":"B40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3389\/fimmu.2016.00364","article-title":"Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output.","volume":"7","author":"Pascutti","year":"2016","journal-title":"Front Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/cells10020277","article-title":"Broad-spectrum antibiotics deplete bone marrow regulatory T Cells.","volume":"10","author":"Han","year":"2021","journal-title":"Cells."},{"key":"B42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2016-03-708594","article-title":"Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota.","volume":"129","author":"Josefsdottir","year":"2017","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7314\/apjcp.2014.15.1.61","article-title":"Prognostic factors in adult patients with solid cancers and bone marrow metastases.","volume":"15","author":"Hung","year":"2014","journal-title":"Asian Pac J Cancer Prev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0300891619839864","article-title":"Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis.","volume":"105","author":"Wang","year":"2019","journal-title":"Tumori."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center.","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1820443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:05Z","timestamp":1783316285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1820443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":45,"alternative-id":["10.3389\/fmed.2026.1820443"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1820443","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1820443"}}